Advances in mRNA nanomedicines for malignant brain tumor therapy

Q1 Engineering

Smart Materials in Medicine Pub Date : 2023-01-01 DOI:10.1016/j.smaim.2022.11.001

Ting Deng , Ikram Hasan , Shubham Roy , Yue Liu , Baozhu Zhang , Bing Guo

{"title":"Advances in mRNA nanomedicines for malignant brain tumor therapy","authors":"Ting Deng , Ikram Hasan , Shubham Roy , Yue Liu , Baozhu Zhang , Bing Guo","doi":"10.1016/j.smaim.2022.11.001","DOIUrl":null,"url":null,"abstract":"<div><p>Nowadays, malignant brain tumors are still mostly lethal diseases with poor prognosis and a clinical median survival rate of fewer than 2 years after therapeutic intervention. It is difficult to achieve complete remission of brain tumors due to blood-brain barrier (BBB) and a lack of efficient drug delivery systems to targeted transportation of brain tumor medicines. Nanoparticle delivery systems have shown merits including stability and high carrier capacity for the transportation of different drugs to treat brain tumors. The application of mRNA nanomedicines brings in great promise not only in COVID-19, but also for malignant brain tumor immunotherapy. The appropriate delivery system facilitates mRNA delivery efficiency and enhances the immune response successfully, for optimal treatment outcomes on malignant brain tumors. Herein, we do an updated review on the development of mRNA nanomedicines for malignant brain cancer treatment. We focus on how to design mRNA-loaded nanoparticle-based delivery systems with optimized pharmacokinetics and pharmacodynamics for efficient therapy of brain cancers. In addition, we point out the challenges and solutions for further development of mRNA nanomedicines for brain cancer therapy. We hope this review would stimulate interest among researchers with different backgrounds and expedite the translation from bench to bedside for the mRNA nanomedicines.</p></div>","PeriodicalId":22019,"journal":{"name":"Smart Materials in Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Smart Materials in Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590183422000527","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Engineering","Score":null,"Total":0}

引用次数: 1

Abstract

Nowadays, malignant brain tumors are still mostly lethal diseases with poor prognosis and a clinical median survival rate of fewer than 2 years after therapeutic intervention. It is difficult to achieve complete remission of brain tumors due to blood-brain barrier (BBB) and a lack of efficient drug delivery systems to targeted transportation of brain tumor medicines. Nanoparticle delivery systems have shown merits including stability and high carrier capacity for the transportation of different drugs to treat brain tumors. The application of mRNA nanomedicines brings in great promise not only in COVID-19, but also for malignant brain tumor immunotherapy. The appropriate delivery system facilitates mRNA delivery efficiency and enhances the immune response successfully, for optimal treatment outcomes on malignant brain tumors. Herein, we do an updated review on the development of mRNA nanomedicines for malignant brain cancer treatment. We focus on how to design mRNA-loaded nanoparticle-based delivery systems with optimized pharmacokinetics and pharmacodynamics for efficient therapy of brain cancers. In addition, we point out the challenges and solutions for further development of mRNA nanomedicines for brain cancer therapy. We hope this review would stimulate interest among researchers with different backgrounds and expedite the translation from bench to bedside for the mRNA nanomedicines.

查看原文本刊更多论文

信使核糖核酸纳米药物治疗恶性脑肿瘤的研究进展

目前恶性脑肿瘤仍多为致死性疾病，预后较差，经治疗干预后临床中位生存率不足2年。由于血脑屏障(BBB)的存在和缺乏有效的药物输送系统来靶向运输脑肿瘤药物，使脑肿瘤难以完全缓解。纳米颗粒输送系统在输送治疗脑肿瘤的不同药物方面具有稳定性和高运载能力等优点。mRNA纳米药物的应用不仅在COVID-19的治疗中，而且在恶性脑肿瘤的免疫治疗中都有很大的前景。合适的递送系统可以提高mRNA的递送效率，并成功增强免疫应答，从而达到恶性脑肿瘤的最佳治疗效果。在此，我们对mRNA纳米药物治疗恶性脑癌的最新进展进行了综述。我们专注于如何设计具有优化药代动力学和药效学的mrna负载纳米颗粒递送系统，以有效治疗脑癌。此外，我们还指出了mRNA纳米药物在脑癌治疗中的进一步发展所面临的挑战和解决方案。我们希望这篇综述能够激发不同背景的研究人员的兴趣，加快mRNA纳米药物从实验室到临床的转化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊